Last updated: October 13, 2024
Sponsor: Duzce University
Overall Status: Active - Recruiting
Phase
4
Condition
N/ATreatment
19-gauge
22-gauge
Clinical Study ID
NCT06643520
EUS-LB
Ages 18-80 All Genders
Study Summary
Eligibility Criteria
Inclusion
Inclusion Criteria:
- All patients with unexplained elevation of liver enzymes and suspected hepaticparanchymal disease
Exclusion
Exclusion Criteria:
Patients who had malignancy
Patients who have decompensated cirrhosis
Presence of ascites
Patients with coagulopathy (platelets < 50.000 μ/ mL and INR > 1.5)
The use of anticoagulant agents
Pregnancy
Unable to provide written informed consent
Study Design
Total Participants: 82
Treatment Group(s): 2
Primary Treatment: 19-gauge
Phase: 4
Study Start date:
July 01, 2024
Estimated Completion Date:
April 01, 2025
Connect with a study center
Duzce University
Duzce, 81620
TurkeyActive - Recruiting
Not the study for you?
Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.